- Home
- MRM vs PCSA Comparison
MRM vs PCSA Comparison
Compare MRM & PCSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MRM | PCSA |
|---|---|---|
| Founded | 2000 | 2011 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.8M | 14.7M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | MRM | PCSA |
|---|---|---|
| Price | $2.05 | $0.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 88.8K | ★ 1.0M |
| Earning Date | 05-22-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $55,915,220.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $51.31 | ★ N/A |
| Revenue Growth | ★ 12.79 | N/A |
| 52 Week Low | $0.34 | $0.15 |
| 52 Week High | $4.45 | $1.33 |
Technical Indicators
Market Signals| Indicator | MRM | PCSA |
|---|---|---|
| Relative Strength Index (RSI) | 46.23 | 26.56 |
| Support Level | $2.02 | $0.26 |
| Resistance Level | $2.33 | $0.30 |
| Average True Range (ATR) | 0.09 | 0.03 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 22.22 | 14.11 |
Price Performance
Historical ComparisonAbout MRM MEDIROM Healthcare Technologies Inc.
MEDIROM Healthcare Technologies Inc provides health services. The company is a franchiser and operator of healthcare salons and operates in segments namely Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty Segment. The company generates a majority of its revenue from the Relaxation Salon business segment. Geographically, the company generates a maximum share of its revenue from Japan.
About PCSA Processa Pharmaceuticals Inc.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).